Psychedelic Inspired Medicines

We are pioneering medicines that have the potential to maintain the therapeutic benefits of psychedelics, without the hallucinogenic effects.

Experience Modern Mind Care

with Psychedelic Inspired Medicines

Derived from psychedelics

zero to negligible hallucination effect

Prescribed by a Doctor

in accordance with diagnosis, for the purpose of healing

Picked up at a Pharmacy

at-home use with daily or weekly administration

Addiction is a Brain Disease

21 million Americans have at least one addiction, yet only 10% of those individuals receive treatment4. What’s worse is that often treatment comes with swapping one addictive substance for another. Addiction is a brain disease, driven by a single disease process: the dysregulation of dopamine, a potent neurotransmitter, in the brain’s reward/pleasure center located in the midbrain.

Developing 18-MC to Treat the Cause of the Brain Disease that is Addiction

We are developing 18-MC to treat the cause of the brain disease that is addiction, rather than merely substituting one addictive substance for another less harmful one. Sustained mental healing requires addressing the root cause and a comprehensive approach for the entire patient journey.

Cue-induced reinstatement, or relapse,  is when an addict is prompted by their surroundings to consume a harmful substance (example: The clink of a wine glass at a dinner party for an alcoholic).

Our intent is not to put people on a pill a day for the rest of their lives, we want to solve for the one of the most common challenging parts of addiction, cue-induced relapse

JR Rahn

Cofounder & Co-CEO of MindMed

Advancing the “Antibiotic of Addiction”

Dr. Stanley Glick (Chair of MindMed’s Scientific Advisory Board) invented 18-MC as a solution for addiction.

18-MC: The Next-Gen Version of Ibogaine

The Need for a Safer Ibogaine

Ibogaine is a Schedule 1 substance extracted from the West Africa iboga shrub with anti-addictive properties but has potential to induce heart attacks

Our Solution

Our scientists and chemists have invented a better version of ibogaine, a derivative called 18-MC

18-MC for Treating Addiction

Designed to correct the dysregulation in the brain’s reward/pleasure center to treat addiction without the hallucinogenic and potential negative side effects of ibogaine

Our [MindMed’s] approach to addiction is, why not treat the cause of the disease in the brain as opposed to using less effective substitution and aversion therapies or intervening at the point at which you’re providing a life-saving measure?”

Stephen Hurst

Cofounder & Co-CEO of MindMed

Generation Adderall Has Grown Up


Adult suffering in US from ADHD5


Adults with ADHD who are receiving treatment6


Between 2007 and 2016 alone, the rate amongst adults increased by 123%. 7

While ADHD is often associated with children and adolescents, adults living with the disease face numerous challenges from debilitating struggles with time management and impulsivity to mood swings and disorganization.

Existing medicines to treat ADHD can be highly addictive themselves and have dangerous long term effects on health. Many people do not get treatment, and many prefer to suffer versus taking the risks associated with treatment.

Microdosing for Macro Healing

Microdosing refers to a smaller, non-hallucinogenic dose of LSD. In these cases, the medicinal properties of the compound address the illness and may not require a hallucinogenic dose as a component of healing.

Extensive anecdotal evidence suggests microdosing Psilocybin & LSD may:

  • Increase focus
  • Decrease anxiety
  • Increase creativity
  • Improve mood

Rigorous scientific trials are in progress to validate these claims and ensure the highest standards of quality, safety, and efficacy for medical use if approved. This is where MindMed’s Microdosing Division comes in.

Clinical Trial Progress

Learn more about clinical collaborations with Dr. Matthias Liechti & Liechti Lab at University Hospital Basel (Switzerland) and Dr. Kim Kuypers, the leading global expert in the clinical science of Microdosing, at Maastricht University (Netherlands)